CURRICULUM VITAE
DATE:
NAME:
SOTOLONGO
Last Name (surname)
POSITION TITLE:
15/Feb/2011
ROBERTO
First Name (given name)
Middle Initial(s)
Medical Doctor
OFFICE ADDRESS:
CONTACT INFORMATION:
Kendall South Medical Center, Inc.
2433 SW 147 Avenue
Miami, Florida, 33185 USA
PROFESSIONAL LICENSURE:
Telephone: 305-388-1118
Fax: 305-223-2973
e-Mail: rsotolongomd@gmail.com
ME102263
EDUCATION/TRAINING:
(Include baccalaureate or other initial professional education such as nursing, postdoctoral training, GCP training.)
DEGREE
INSTITUTION AND LOCATION
National Health Institute
Miami, Florida
Board Certified in Internal Medicine
Miami, Florida. USA
(if applicable)
GCP / SAE
2010
MD
2008
Internal Medicine Residency Program
Mayaguez, Puerto Rico. PR
MD
Doctor in Medicine
MD
National University Pedro Henriquez Ureña
Dominican Republic
Bachelor’s Degree in Science
YEAR(s)
MD
San German, Puerto Rico
07/2005 –
06/2008
08/1995 –
06/2001
08/1990 –
05/1995
FIELD OF STUDY
CGP/ ICH/ Belmot
Report / SAE
Internal Medicine
Internal Medicine
MD
MD
Specialization: INTERNAL MEDICINE
POSITIONS AND EMPLOYMENT:
2009 – Present
12/2008 – 08/2009
Medical Director / Principal Investigator
Kendall South Medical Center, Inc. Miami, Florida. USA
Hospitalist
Central Florida Hospitalist Partners. Orlando, FL USA
10/2008 – 11/2008
Hospitalist
03/2003 – 06/2005
Veterans Affairs Hospital. Martinsburg, WV USA
Medical Assistant
Mega Testing Clinic Center. Miami, Florida USA
OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:
2005
Educational Commission for Foreign Medical Graduate
2008
Board Certified in Internal Medicine by American Board of Internal Medicine
RESEARCH EXPERIENCE:
List last 3 years of RESEARCH EXPERIENCEA Historical-controlled, Multicenter, Double-blind, Randomized Trial to
Assess the Efficacy and Safety of Conversion to xxxx Monotherapy in
Subjects with Partial-onset Seizures
Phase III, Ongoing
Sub Investigator
07/2010
1
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
of the Efficacy and Safety of xxxx as Monotherapy for Type 2 Diabetes
Phase IIIb/IV
Sub Investigator, Ongoing
06/2010
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
of the Efficacy and Safety of xxxx as Add-On to Pioglitazone Therapy for
Type 2 Diabetes Mellitus
Phase IIIb/IV
Sub Investigator, Ongoing
06/2010
Multicentre, Randomised, Double-Blind, Placebo-Controlled,
Parallel-Group, International Phase III Study with a 24-week
Extension Period to Evaluate the Safety and Efficacy of xxxx Daily in Patients
with Type 2 Diabetes who have Inadequate Glycaemic Control on a DPP-4
inhibitor (Sitagliptin) Alone or in Combination with Metformin
Phase III, Ongoing
Principal Investigator
4/20/2010 - Present
Multicentre, randomised, double-blind, age-stratified, placebo controlled
4/20/2010 - Present
phase III study with a 28-week extension period to evaluate the efficacy and
safety of xxxx once daily in patients with type 2 diabetes, cardiovascular disease
and hypertension, who exhibit inadequate glycaemic control on usual care.
Phase III, Ongoing
Principal Investigator
Multicenter, Randomized, Active-Control, Study to Evaluate the
Cardiovascular Safety of xxxxx and xxxxx in Subjects With Gout and
Cardiovascular Comorbidities
Phase IIIb, Ongoing
Sub Investigator
4/2010 - Present
A Multicenter, Randomized, Double Blind, Placebo and xxxx
Controlled, Phase 2 Study to Evaluate xxxx in Medical Management
of Subjects with Hyperuricosuria and Calcium Oxalate Stones
Phase IIIb, ongoing
Sub Investigator
4/2010 - Present
A multi-center, randomized, double-blind, placebo-controlled, parallel group,
repeated-dose study to evaluate the efficacy, safety, tolerability and
pharmacokinetics of three different dosing regimens of xxxxx in patients with
persistent asthma.
Phase IIa, 38 patients
Principal Investigator
03/2010 – 7/2010
Randomized, Double Blind Placebo and xxxxx controlled multicenter
Study of the analgesic efficacy and safety of xxxxxx in patients with
Osteoarthritis of the knee.
Phase III, 47 patients
Sub-Investigator
12/2009 – 07/2010
Randomized, Double Blind Placebo and xxxxx controlled multicenter
Study of the analgesic efficacy and safety of xxxxxx in patients with
Osteoarthritis of the hip or knee.
Phase III, 58 patients
Sub-Investigator
10/2009 – 06/2010
2
A worldwide, Multicenter, Double-Blind, Randomized,
Placebo-controlled, Dose Ranging Study to Evaluate the Efficacy,
Safety, and Tolerability of xxxxx when added to ongoing therapy
with Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin
Receptor Blocker (ARB) in patients with Diabetes and Hypertension
Phase III, 5 patients
Sub-Investigator
10/2009 – 04/2010
Multicenter, Randomized, Long Term Study of the Safety of xxxxx in Patients
with Osteoarthritis of the Knee or Hip
Phase III, 56 ongoing
Sub-Investigator
09/2009
Chronic Lower Back Pain Study. Phase III. 20 Patients
09/2008 – 07/2009
“Prevalence of Dementia in Patients with Parkinson’s Disease”
Advanced Cardiology Center Mayaguez, Puerto Rico
Internal Medicine Residency Program
01/2008 – 05/2008
Osteoarthritis of the Knee in Puerto Rico. Phase IV, 25 Patients
08/2007 – 04/2008
“Incidence of Bradycardia in patients with Myotonic Dystrophy”
Advanced Cardiology Center Mayaguez, Puerto Rico
Internal Medicine Residency Program
01/2007 – 05/2007
Influenza Study in hospital patients. 40 patients
Internal Medicine Residency program
Mayaguez, Puerto Rico
10/2005
“Growth Delay in Pediatrics Patients”
Performed at Dr. Luis Aybar Hospital
Dominican Republic
08/2000 – 04/2001
3